JPMorgan lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $20 from $37 and keeps a Neutral rating on the shares. The firm updated its model and lowered its price target following top-line results from the phase 3 RISE UP trial for Pyrukynd in sickle cell disease. The firm also made adjustments to its longer-term expense assumptions and its revenue builds for mitapivat in pyruvate kinase deficiency and mitapivat in thalassemia.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGIO:
- Agios Pharmaceuticals price target lowered to $25 from $40 at Goldman Sachs
- Leerink upgrades Agios to Outperform after 51% pullback
- Agios Pharmaceuticals upgraded to Outperform from Market Perform at Leerink
- Agios Pharmaceuticals price target lowered to $32 from $54 at BofA
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!